ArticleJournal of intensive medicine2025

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial.

Norberto Chavez-Tapia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.